SARS-CoV-2 variants from mink evade inhibition by antibodies

It has been known for about a year that minks can become infected with SARS-CoV-2. The virus had been transmitted from humans to farmed mink and mutated in infected animals. Mutations were acquired in the spike protein, which is crucial for the entry of the virus into host cells and represents the central point of attack for antibodies. These SARS-CoV-2 variants from mink were transmitted back to humans, raising concerns that minks could be a continuing source of infection of humans with SARS-CoV-2 variants with altered biological properties. Researchers at the German Primate Center (DPZ) - Leibniz Institute for Primate Research in Göttingen, Germany, have now shown that an antibody used for COVID-19 therapy is unable to effectively inhibit SARS-CoV-2 harboring a spike mutation acquired in minks. In addition, the mutation reduced the inhibition of the virus by antibodies produced in SARS-CoV-2 infected humans. These results show that SARS-CoV-2 can acquire mutations in minks that may reduce control of the virus by the human immune system. The study and findings have been published in Cell Reports.

Neutralization of SARS‐CoV‐2 by highly potent, hyperthermostable, and mutation‐tolerant nanobodies

Evasion of vaccine-induced humoral immunity by emerging sub-variants of SARS -CoV-2

SARS-CoV-2 variants: A double-edged sword? - Manasi P Jogalekar, Anurag Veerabathini, Prakash Gangadaran, 2021

Viruses, Free Full-Text

Molecular variants of SARS-CoV-2: antigenic properties and current vaccine efficacy

Evasion of vaccine-induced humoral immunity by emerging sub-variants of SARS -CoV-2

The Omicron variant is highly resistant against antibody-mediated neutralization – implications for control of the COVID-19 pandemic

Structure and Mutations of SARS-CoV-2 Spike Protein: A Focused Overview

SARS-CoV-2 variant B.1.617 is resistant to bamlanivimab and evades antibodies induced by infection and vaccination - ScienceDirect

Multiple SARS-CoV-2 variants escape neutralization by vaccine-induced humoral immunity

Pharmacological activation of STING blocks SARS-CoV-2 infection

SARS-CoV-2 variants, spike mutations and immune escape